Noxxon Pharma makes addition to supervisory board
This article was originally published in Scrip
Berlin, Germany and Boston, USA-based Noxxon Pharma has named Don deBethizy to the company's supervisory board. In his last position as president and chief executive officer of Santaris Pharma, Mr deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was executive chair of Danish bio-venture firm, Contera Pharma. Noxxon is developing a new class of proprietary therapeutics called Spiegelmers, which are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies.